Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Comparative CRS risk across CAR-T constructs in DLBCL in real-world cohorts

View Full Paper
Ask AI
Bookmark
Share

Authors

SASafa Saadat AfridiASAl-Aman Shaukat

Discussion

Loading...

Member takes

Overview

Retrospective analysis found similar CRS incidence in DLBCL across CAR-T therapies, suggesting product-specific inflammatory responses.

Key Points

  • This study evaluates cytokine release syndrome (CRS) risk across commercial CAR-T therapies in DLBCL patients.
  • Retrospective analysis using TriNetX Global Collaborative Network
  • Adult DLBCL patients receiving CAR-T therapies were included
  • Propensity score matching used for cohort balance
  • Primary outcome: CRS diagnosis within 90 days post-CAR-T
  • Secondary outcomes include inflammatory biomarkers post-infusion
  • CRS incidence varied across CAR-T constructs but was not significantly different in matched comparisons
  • In observational analyses, the CRS rates were highest with axi-cel and tisa-cel
  • Tocilizumab usage differed among patients receiving different CAR-T therapies
  • Inflammatory biomarker levels varied significantly across constructs despite similar CRS incidence
  • Findings suggest the need for refined monitoring and management strategies for CRS.

Cite This Study

Afridi et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e274https://doi.org/10.1182/blood-2025-5504
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Early intervention for cytokine release syndrome after chimeric antigen receptor T-cell therapy is associated with an increased risk of cytopenias and infections in patients with large B-cell lymphoma2025
  2. 2Axi-cel vs. tisa-cel vs. liso-cel in R/R DLBCL: Meta-analysis of the efficacy-safety trade-off.2026
  3. 3Prolonged Cytokine Release Syndrome Is Associated With Hypofibrinogenemia After CD19-Directed CAR T-Cell Therapy in Adult Patients With Relapsed/Refractory Lymphoma2026 · 1 citations
  4. 4Beyond the trial: Real-world CRS, icans, and healthcare burden of CAR T-cell therapy across US oncology practices2025 · 1 citations
  5. 5Decreased renal function predicts severe cytokine release syndrome after <scp>CAR</scp> ‐T‐cell therapy for large B‐cell lymphoma2026 · 2 citations